SEC Comment Letter 0000000000-24-011331 to Dianthus Therapeutics, Inc. /DE/ (DNTH) (CIK 0001690585) (DNTH)
Dianthus Therapeutics, Inc. /DE/ (DNTH) (CIK 0001690585)
Date: Oct. 7, 2024 · CIK: 0001690585 · Accession: 0000000000-24-011331
AI Filing Summary & Sentiment
File numbers found in text: 333-282446
Letter
October 7, 2024 Adam Veness General Counsel Dianthus Therapeutics, Inc. 7 Times Square, 43rd Floor New York, NY 10036 Re:Dianthus Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-282446 Filed October 1, 2024 Dear Adam Veness: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Branden Burns
Show Raw Text
October 7, 2024
Adam Veness
General Counsel
Dianthus Therapeutics, Inc.
7 Times Square, 43rd Floor
New York, NY 10036
Re:Dianthus Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-282446
Filed October 1, 2024
Dear Adam Veness:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Branden Burns